MedTrace Logo

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

NCT05153135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4320

Last updated 2021-12-21

No results posted yet for this study

Summary

The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.

Conditions

Interventions

DRUG

Ribociclib

Participants who initiated CDK4/6i therapy

DRUG

Palbociclib

Participants who initiated CDK4/6i therapy

DRUG

Abemaciclib

Participants who initiated CDK4/6i therapy

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-08
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153135 on ClinicalTrials.gov